{"contentid": 488131, "importid": NaN, "name": "Further vindication for Novartis in radioligand space", "introduction": "Swiss pharma giant Novartis has announced a positive result of its Phase III study with the radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer.", "content": "<p>Swiss pharma giant Novartis (NOVN: VX) has announced a positive result of its Phase III study with the radioligand therapy <sup>177</sup>Lu-PSMA-617 in patients with advanced prostate cancer.</p>\n<p>The VISION study is evaluating the efficacy and safety of <sup>177</sup>Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone.</p>\n<p><span class=\"pullQuote\">\"We intend to submit these data to regulatory authorities as soon as possible\"</span>Both primary endpoints of overall survival and radiographic progression-free survival were met, helping to move closer the ambition of becoming the targeted treatment for at least 80% of patients with advanced prostate cancer.</p>\n<p>The safety profile was consistent with data reported in previous clinical studies.</p>\n<p>John Tsai, head of global drug development and chief medical officer for Novartis, said: &ldquo;Patients with mCRPC have a less than one in six chance of surviving five years and need new treatment options.</p>\n<p>&ldquo;These groundbreaking data confirm our belief in the potential of <sup>177</sup>Lu-PSMA-617 to reimagine outcomes for these patients through phenotypic precision medicine. We intend to submit these data to regulatory authorities as soon as possible.&rdquo;</p>\n<p>177Lu-PSMA-617, which had previously shown promising Phase II data, was acquired by Novartis in its 2018 buy of Endocyte for $2.1 billion. The Basel-based company is a leader in the radioligand therapy space, having also acquired Advanced Accelerator Applications and its on-market drug Lutathera (lutetium Lu 177 dotatate) in 2018.</p>\n<p>Novartis has established global expertise and specialized supply chain and manufacturing capabilities across its network of four radioligand therapy production sites, and is further increasing capacity to ensure delivery of radioligand therapies like <sup>177</sup>Lu-PSMA-617.</p>\n<p>&nbsp;</p>", "date": "2021-03-23 17:14:00", "meta_title": NaN, "meta_keywords": "Novartis, radioligand, Lu-PSMA-, patients, data, cancer, prostate, advanced, therapy, study, Phase, vindication, result, positive, announced, space, giant", "meta_description": "Swiss pharma giant Novartis has announced a positive result of its Phase III study with the radioligand therapy 177Lu-PSMA-617 in patients with advanced prostat", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-23 16:47:11", "updated": "2021-03-23 17:14:40", "access": NaN, "url": "https://www.thepharmaletter.com/article/further-vindication-for-novartis-in-radioligand-space", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_novartis_big.jpg", "image2id": "2020_novartis_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Genito-urinary, Men's Health, Oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "Switzerland", "company_tag": "Novartis", "drug_tag": "177Lu-PSMA-617", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-23 17:14:00"}